Lunit partners with SITC to provide AI biomarker platform to global researchers

Lunit, a Korean AI company specializing in medical imaging and diagnostics, said it has partnered with the Society for Immunotherapy of Cancer (SITC) to offer its AI-powered biomarker discovery platform to SITC-affiliated researchers.

The two partners announced Monday the launch of the Lunit Research Program, which provides SITC members with temporary free access to Lunit SCOPE IO, an AI-driven biomarker analysis tool.

Lunit SCOPE IO is trained on large-scale hematoxylin and eosin (H&E) slide image data. It quantifies tumor-infiltrating lymphocytes (TILs), a key indicator of immunotherapy response, and analyzes the tumor microenvironment (TME) to classify immune phenotypes into three categories: inflamed, immune-excluded, and immune-desert.

The program is open to SITC members affiliated with academic or nonprofit research institutions who hold an MD or PhD. Applicants must have expertise in oncology, pathology, or immunology and will be selected based on their research proposal and CV.

The application period runs through April 30, with selections taking two to three months. Research is expected to begin in the summer.

Participants will receive complimentary access to Lunit SCOPE IO for H&E slide analysis and can opt for slide scanning services at cost.

SOURCE: Korea Biomedical Review